Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 15/20 | 0.56 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29476401 | 1.00 | IL23R (0.56) | IL23RKISS1R | |
| SCHEMBL29476589 | 0.93 | KISS1R (0.54) | IL23RKISS1R | |
| SCHEMBL29476420 | 0.93 | KISS1R (0.54) | IL23RKISS1R | |
| SCHEMBL29476448 | 0.93 | KISS1R (0.54) | IL23RKISS1R | |
| SCHEMBL30198819 | 0.93 | ACE (0.54) | IL23RKISS1R | |
| SCHEMBL29476578 | 0.93 | IL23R (0.59) | IL23RKISS1R | |
| SCHEMBL29476380 | 0.93 | IL23R (0.59) | IL23RKISS1R | |
| SCHEMBL29476531 | 0.91 | IL23R (0.52) | IL23RKISS1R | |
| SCHEMBL29476609 | 0.91 | IL23R (0.52) | IL23RKISS1R | |
| SCHEMBL30092951 | 0.90 | KISS1R (0.54) | IL23RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271400-A | Peptide composition | 节奏制药公司 | 2024-07-02 | — | — | CN | claimed |
| CN-118240012-A | Peptide composition | 节奏制药公司 | 2024-06-25 | — | — | CN | claimed |
| US-20250188124-A1 | PEPTIDE COMPOSITIONS | RHYTHM PHARMACEUTICALS, INC. | 2025-06-12 | — | — | US | disclosed |
| CN-105492456-B | Peptide composition | 节奏制药公司 | 2024-11-01 | — | — | CN | disclosed |
| US-12077612-B2 | Peptide compositions | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| CN-118271400-A | Peptide composition | 节奏制药公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118240012-A | Peptide composition | 节奏制药公司 | 2024-06-25 | — | — | CN | disclosed |
| EP-4216979-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | Rhythm Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116507353-A | Methods of treating melanocortin-4 receptor pathway-related disorders | 节奏制药公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-115957297-A | Pharmaceutical composition | 节奏制药公司 | 2023-04-14 | — | — | CN | disclosed |
| CN-115957296-A | Pharmaceutical composition | 节奏制药公司 | 2023-04-14 | — | — | CN | disclosed |
| WO-2022067086-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | RHYTHM PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188124-A1 | PEPTIDE COMPOSITIONS | MC4R, MC3R, MC5R | IL23R 473/4885KISS1R 170/4885 |
| US-12077612-B2 | Peptide compositions | MC4R, MC3R, MC5R | IL23R 473/4885KISS1R 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.